The coadministration of MMI with a moderate dose of I2 (MMI + M-I2) prevented the decline in T4 (2.5 ± 0.3) and kept the dyslipidemia and inflammation markers at basal values (TC: 63.5 ± 7.0 and LDL-C: 10.5 ± 1.9; sCD163: 0.07 ± 0.01), but without fully reestablishing T3 values (59.7 ± 3.2). This evidence concerns the gene CD163 and metabolic syndrome.